Peptide receptor radionuclide therapy targeting the cholecystokinin-2 receptor: Preclinical and first clinical experience in small cell lung cancer
Preprint
Abstract
Rationale: Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors (NETs), enabling targeted radiation delivery via radiolabeled peptides. Small cell lung cancer (SCLC) remains a major therapeutic challenge due to its aggressive nature and poor prognosis. Despite advances, relapse rates are high and effective therapies are limited. We previously demonstrated the diagnostic potential of the cholecystokinin-2 receptor-targeting minigastrin analog [ 68 Ga]Ga-DOTA-MGS5 in PET/CT imaging in different NETs. Building on this, we developed and evaluated [ 177 Lu]Lu-DOTA-MGS5 as a therapeutic PRRT agent. Methods: Preclinical studies investigating the cellular internalization and intracellular distribution over time in A431 cells were performed using the fluorescent tracer ATTO-488-MGS5. Short-and long-term cytotoxic effects of [ 177 Lu]Lu-DOTA-MGS5 were evaluated on the same cell line using trypan blue exclusion and clonogenic survival assays. CCK2R expression was assessed by immunohistochemistry in 42 SCLC tissue specimens. In addition, the first PRRT with [ 177 Lu]Lu-DOTA-MGS5 was conducted in a patient with extensive disease SCLC after confirming CCK2R-positive uptake in [ 68 Ga]Ga-DOTA-MGS5 PET/CT. Results: Rapid binding and internalization into A431-CCK2R cells, with progressive accumulation in intracellular compartments, was observed for ATTO-488-MGS5. Short-term irradiation effects of [ 177 Lu]Lu-DOTA-MGS5 were comparable for 4 h and 24 h incubation and lay between the effects obtained with 2 and 4 Gy of EBRT. Clonogenic survival of A431-CCK2R cells incubated with the increasing radioactivity of [ 177 Lu]Lu-DOTA-MGS5 decreased in a dose-dependent manner. Immunohistochemistry on SCLC specimens confirmed moderate to high CCK2R expression in 16 of 42 SCLC samples. In the first patient with SCLC treated with four cycles of [ 177 Lu]Lu-DOTA-MGS5 with a total activity of 17.2 GBq, no signs of toxicity were noticed. Conclusions: The preclinical and clinical results confirm the feasibility of [ 177 Lu]Lu-DOTA-MGS5 PRRT in patients with SCLC and support further clinical studies investigating the therapeutic value and clinical applicability of this new CCK2R-targeted theranostic approach in larger patient cohorts.Keywords
This publication has 34 references indexed in Scilit:
- Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Cholecystokinin-2 receptor targeting by [68Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- The Unique Importance of Differentiation and Function in Endocrine NeoplasiaEndocrine Pathology, 2023
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung CancerJAMA, 2022
- In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&TEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practiceESMO Open, 2022
- Overview of the 2022 WHO Classification of Neuroendocrine NeoplasmsEndocrine Pathology, 2022
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsNew England Journal of Medicine, 2017
- Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer researchCancer Letters, 2012
- Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targetingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003